Status and phase
Conditions
Treatments
About
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
550 participants in 2 patient groups
Loading...
Central trial contact
UCB Cares; UCB Cares
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal